Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 49
Filter
1.
Curr Drug Saf ; 19(2): 244-247, 2024.
Article in English | MEDLINE | ID: mdl-37496243

ABSTRACT

BACKGROUND: Proton pump inhibitors (PPIs) are one of the most used classes of drugs. For most indications, PPIs are only recommended up to 8 weeks duration. However, PPI use continues to expand. Regular and prolonged use of PPIs should be avoided because of the risk of adverse events. OBJECTIVES: The main objective of this study was to (1) investigate the extent of PPI usage in people aged 65 or older in the province of British Columbia (BC), Canada, (2) provide an overview of the harms associated with the long-term use of PPIs. METHODS: We examined utilization trends of the PPIs in BC since the year 2009 using PharmaNet, BC's medication dispensing database where the information is accessible to community pharmacists. We performed a comprehensive literature search for relevant reviews reporting harms associated with long-term use of PPIs. A search was conducted from January 2014 to June 2022. RESULTS: Between 2000 and 2018 BC's population grew by 20%, but the use of PPIs escalated to 257%. Of these older British Columbians, 62% had a cumulative exposure exceeding 2 years and 42% exceeded 5 years. This is alarming because the recommended treatment duration is 4-12 weeks for common indications including reflux esophagitis, and duodenal and gastric ulcers. Only 13.5% were dispensed PPIs for 90 days or less. Patients on long-term PPI therapy should be reassessed. Adverse events of PPI use are common among older adults. We identified over 217 systematic reviews published during the last 8 years of specific harms associated with long-term daily usage of PPIs. These harms include increased risks of death, cardiovascular disease, acute renal injury, chronic kidney disease, dementia, fractures, hypomagnesemia, iron deficiency, vitamin B12 deficiency, enteric infection (including C. difficile), pneumonia, and neoplasia (gastric cancer, carcinoids, and colon cancer), and drug interactions. CONCLUSION: This study revealed a high prevalence of PPI use among elderly populations in BC, Canada. The overutilization of PPIs is often a result of failure to re-evaluate the need for continuation of therapy. Published studies identified signals of serious harm from long-term PPI exposure. Healthcare providers with patients can reverse the relentless expansion of long-term PPI exposure by discussing the expected benefits and potential harms.


Subject(s)
Cardiovascular Diseases , Clostridioides difficile , Aged , Humans , Proton Pump Inhibitors/adverse effects , British Columbia/epidemiology , Cardiovascular Diseases/drug therapy
2.
Pilot Feasibility Stud ; 9(1): 84, 2023 May 18.
Article in English | MEDLINE | ID: mdl-37202822

ABSTRACT

BACKGROUND: Polypharmacy is associated with poorer health outcomes in older adults. Other than the associated multimorbidity, factors contributing to this association could include medication adverse effects and interactions, difficulties in managing complicated medication regimes, and reduced medication adherence. It is unknown how reversible these negative associations may be if polypharmacy is reduced. The purpose of this study was to determine the feasibility of implementing an operationalized clinical pathway aimed to reduce polypharmacy in primary care and to pilot measurement tools suitable for assessing change in health outcomes in a larger randomized controlled trial (RCT). METHODS: We randomized consenting patients ≥ 70 years old on ≥ 5 long-term medications into intervention or control groups. We collected baseline demographic information and research outcome measures at baseline and 6 months. We assessed four categories of feasibility outcomes: process, resource, management, and scientific. The intervention group received TAPER (team approach to polypharmacy evaluation and reduction), a clinical pathway for reducing polypharmacy using "pause and monitor" drug holiday approach. TAPER integrates patients' goals, priorities, and preferences with an evidence-based "machine screen" to identify potentially problematic medications and support a tapering and monitoring process, all supported by a web-based system, TaperMD. Patients met with a clinical pharmacist and then with their family physician to finalize a plan for optimization of medications using TaperMD. The control group received usual care and were offered TAPER after follow-up at 6 months. RESULTS: All 9 criteria for feasibility were met across the 4 feasibility outcome domains. Of 85 patients screened for eligibility, 39 eligible patients were recruited and randomized; two were excluded post hoc for not meeting the age requirement. Withdrawals (2) and losses to follow-up (3) were small and evenly distributed between arms. Areas for intervention and research process improvement were identified. In general, outcome measures performed well and appeared suitable for assessing change in a larger RCT. CONCLUSIONS: Results from this feasibility study indicate that TAPER as a clinical pathway is feasible to implement in a primary care team setting and in an RCT research framework. Outcome trends suggest effectiveness. A large-scale RCT will be conducted to investigate the effectiveness of TAPER on reducing polypharmacy and improving health outcomes. TRIAL REGISTRATION: clinicaltrials.gov NCT02562352 , Registered September 29, 2015.

4.
Trials ; 22(1): 746, 2021 Oct 26.
Article in English | MEDLINE | ID: mdl-34702336

ABSTRACT

BACKGROUND: Polypharmacy in older adults can be associated with negative outcomes including falls, impaired cognition, reduced quality of life, and general and functional decline. It is not clear to what extent these are reversible if the number of medications is reduced. Primary care does not have a systematic approach for reducing inappropriate polypharmacy, and there are few, if any, approaches that account for the patient's priorities and preferences. The primary objective of this study is to test the effect of TAPER (Team Approach to Polypharmacy Evaluation and Reduction), a structured operationalized clinical pathway focused on reducing inappropriate polypharmacy. TAPER integrates evidence tools for identifying potentially inappropriate medications, tapering, and monitoring guidance and explicit elicitation of patient priorities and preferences. We aim to determine the effect of TAPER on the number of medications (primary outcome) and health-related outcomes associated with polypharmacy in older adults. METHODS: We designed a multi-center randomized controlled trial, with the lead implementation site in Hamilton, Ontario. Older adults aged 70 years or older who are on five or more medications will be eligible to participate. A total of 360 participants will be recruited. Participants will be assigned to either the control or intervention arm. The intervention involves a comprehensive multidisciplinary medication review by pharmacists and physicians in partnership with patients. This review will be focused on reducing medication burden, with the assumption that this will reduce the risks and harms of polypharmacy. The control group is a wait list, and control patients will be given appointments for the TAPER intervention at a date after the final outcome assessment. All patients will be followed up and outcomes measured in both groups at baseline and 6 months. DISCUSSION: Our trial is unique in its design in that it aims to introduce an operationalized structured clinical pathway aimed to reduce polypharmacy in a primary care setting while at the same time recording patient's goals and priorities for treatment. TRIAL REGISTRATION: Clinical Trials.gov NCT02942927. First registered on October 24, 2016.


Subject(s)
Polypharmacy , Quality of Life , Aged , Humans , Multicenter Studies as Topic , Pharmacists , Potentially Inappropriate Medication List , Primary Health Care , Randomized Controlled Trials as Topic , Review Literature as Topic
7.
CMAJ Open ; 7(3): E472-E477, 2019.
Article in English | MEDLINE | ID: mdl-31320330

ABSTRACT

BACKGROUND: Most private drug plans in Canada do not use a formulary, which leads to suboptimal drug use. We studied the impact of the adoption of the public formulary by a large private health benefits plan in British Columbia. METHODS: We studied the impact of a change by members of the BC Hospital Employees' Union to have their private drug plan mirror the public formulary as of June 2013. With data from Pacific Blue Cross, we conducted a before-and-after descriptive study using interrupted time-series analysis to study changes in covered drug costs and use for 18 months preceding and following the change. RESULTS: Our cohort averaged 66 000 plan members and dependents over our study period. Following the implementation of the formulary, the number of prescriptions covered by the plan declined by 0.46 prescriptions per member per month (95% confidence interval -0.50 to -0.42), a decline of 23.8% at 1 year. This decreased plan spending by $1.32 million over the 18 months after the coverage change, a 49.7% decline. INTERPRETATION: The adoption of the public formulary by a large private drug plan in BC substantially reduced drug plan expenditures and the volume of prescriptions paid for by the plan. Overall, these results suggest that carefully designed formulary changes could substantially reduce spending by private-sector drug plans on drugs that have more cost-effective therapeutic alternatives.

8.
Health Policy ; 122(3): 250-255, 2018 03.
Article in English | MEDLINE | ID: mdl-29395543

ABSTRACT

OBJECTIVES: To examine and compare the experiences and attitudes of primary care physicians in three different regulatory environments (United States, Canada, and France) towards interactions with pharmaceutical sales representatives, particularly their perspectives on safety information provision and self-reported influences on prescribing. METHODS: We recruited primary care physicians for 12 focus groups in Montreal, Sacramento, Toulouse and Vancouver. A thematic analysis of the interview data followed a five-stage framework analysis approach. RESULTS: Fifty-seven family physicians (19 women, 38 men) participated. Physicians expected a commercial bias and generally considered themselves to be immune from influence. They also appreciated the exchange and the information on new drugs. Across all sites, physicians expressed concern about missing harm information; however, attitudes to increased regulation of sales visits in France and the US were generally negative. A common solution to inadequate harm information was to seek further commercially sourced information. Physicians at all sites also expressed sensitivity to critiques from medical students and residents about promotional interactions. CONCLUSIONS: Physicians have contradictory views on the inadequate harm information received from sales representatives, linked to their lack of awareness of the drugs' safety profiles. Commonly used strategies to mitigate information bias are unlikely to be effective. Alternate information sources to inform prescribing decisions, and changes in the way that physicians and sales representatives interact are needed.


Subject(s)
Attitude of Health Personnel , Bias , Commerce , Drug Industry/standards , Practice Patterns, Physicians' , Primary Health Care , Canada , Drug Prescriptions , Drug-Related Side Effects and Adverse Reactions , Female , France , Humans , Male , Marketing , United States
10.
CMAJ ; 2015 May 11.
Article in English | MEDLINE | ID: mdl-25964391
11.
CMAJ ; 2015 May 04.
Article in English | MEDLINE | ID: mdl-25941266
12.
Health Policy ; 119(2): 224-31, 2015 Feb.
Article in English | MEDLINE | ID: mdl-25498311

ABSTRACT

Prescription drugs are the highest single cost component for employees' benefits packages in Canada. While industry literature considers cost-containment for prescription drug costs to be a priority for insurers and employers, the implementation of cost-containment measures for private drug plans in Canada remains more of a myth than a reality. Through 18 semi-structured phone interviews conducted with experts from private sector companies, unions, insurers and plan advisors, this study explores the reasons behind this incapacity to implement cost-containment measures by examining how private sector employers negotiate drug benefit design in unionized settings. Respondents were asked questions on how employee benefits are negotiated; the relationships between the players who influence drug benefit design; the role of these players' strategies in influencing plan design; the broad system that underpins drug benefit design; and the potential for a universal pharmacare program in Canada. The study shows that there is consensus about the need to educate employees and employers, more collaboration and data-sharing between these two sets of players, and for external intervention from government to help transform established norms in terms of private drug plan design.


Subject(s)
Health Benefit Plans, Employee , Health Care Reform/organization & administration , Insurance, Pharmaceutical Services , Canada , Cost-Benefit Analysis , Health Benefit Plans, Employee/economics , Health Benefit Plans, Employee/organization & administration , Health Care Reform/methods , Humans , Insurance, Pharmaceutical Services/economics , Labor Unions , Organizational Innovation
20.
CMAJ ; 183(6): 728, 2011 Apr 05.
Article in English | MEDLINE | ID: mdl-21398242
SELECTION OF CITATIONS
SEARCH DETAIL
...